Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm. Our purpose – and passion – is to seek out, enable and empower the most promising life science therapeutics innovations.

We help turn new science into new products, improving outcome for patients. And we help create value for innovators, investors and health care systems around the world.

Read more…

Is biotech venture capital investing more to return less?

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...

An update on M&A returns for biotech venture capital

Back in in 2019 Sunstone started sharing studies of European venture capital funded successes – i.e. M&A transactions. In 2021 we started adding US M&A’s to the data and later the same year we evaluated to which extent an IPO impacted the observations made....

Biotech ecosystem contributors!

Biotech ecosystem contributors! In our previous post, we discussed the importance of local investors and how, in a Danish context, they contribute to identifying and scaling local and regional therapeutic innovation. However, not all investors are born equal - and an...

Do local investors make a difference?

Do local investors make a difference? E-mail outreach, online meetings and digital data rooms have become a given when trying to finance a therapeutic innovation! So, do local or regional anchor investors matter when developing a bioinnovation ecosystem? If the local...

Seed & Series A in Denmark

Financing a Danish Biotech company has apparently never been more challenging. Based on feedback from partnering meetings in 2025 it seems that raising Series A financing has become an unprecedented challenge. However, when looking at the available data on the...



Investment Strategy

Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans.

Read more…



Funds

Our portfolio is managed through a series of funds. Fund IV, focusing solely on therapeutics, is actively pursuing new investment opportunities.

Read more…



People

As a team, we represent a broad range of highly relevant education, experience and competencies. Come on in and meet the team.

Read more…



Portfolio

An overview of the companies in our portfolio – currently active, completed M&As and completed IPOs.

Read more…

|

News

Newest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.

Read more…



Contact

Find our visiting address, contact info and some guidance and a contact form for submitting projects for evaluation.

Read more…

New science becomes new products

Since the inception of Sunstone in 2007, we have contributed in bringing several new drugs into the market and have supported a large number of clinical trials:

New drugs approved

Pre-clinical drug candidates

Clinical phase 1 studies

Clinical phase 2 studies

Clinical phase 3 studies

Sunstone Life Science Ventures is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing